2012

• Wilcken, N. (2012), First story - MJA Dr Eric Dark Creative Writing Prize. The Medical Journal of Australia. 197(9), 526. [Abstract]
• Balleine, R., Wilcken, N. (2012), High-Risk Estrogen-Receptor-Positive Breast Cancer: Identification and Implications for Therapy. Molecular Diagnosis & Therapy. 16(4), 235-240. [Abstract]
• Lord, S., Marinovich, M., Patterson, J., Wilcken, N., Kiely, B., Gebski, V., Crossing, S., Roder, D., Gattellari, M., Houssami, N. (2012), Incidence of metastatic breast cancer in an Australian population-based cohort of women with non-metastatic breast cancer at diagnosis. Medical Journal of Australia. 196(11), 688-692. [Abstract]
• Cameron, B., Bennett, B., Li, H., Boyle, F., Desouza, P., Wilcken, N., Friedlander, M., Goldstein, D., Lloyd, A. (2012), Post-cancer fatigue is not associated with immune activation or altered cytokine production. Annals of Oncology. 23(11), 2890-2895. [Abstract]
• Stockler, M., Wilcken, N. (2012), Why is management of cancer pain still a problem?. Journal of Clinical Oncology. 30, 1907-1908. [Abstract]
• McCarthy, N., Mitchell, G., Bilous, M., Wilcken, N., Lindeman, G. (2012), Triple-negative breast cancer: making the most of a misnomer. Asia-Pacific Journal of Clinical Oncology. 8(2), 145-155. [Abstract]
• Goldstein, D., Bennett, B., Webber, K., Boyle, F., de Souza, P., Wilcken, N., Scott, E., Toppler, R., Murie, P., O'Malley, L., McCourt, J., Friedlander, M., Hickie, I., Lloyd, A. (2012), Cancer-related fatigue in women with breast cancer: outcomes of a 5-year prospective cohort study. Journal of Clinical Oncology. 30(15), 1805-1812. [Abstract]
• Venkateswaran, L., Butow, P., Jansen, J., Wilcken, N., Wong, M., Hui, R., Szonyi, G., Gebski, V., Naganathan, V., Horvath, L., Tattersall, M. (2012), Decision making in older patients with advanced cancer: does doctor know best?. Medical Journal of Australia. 196(1), 35-36. [Abstract]

2011

• Wilcken, N. (2011), Nine letters. The Lancet Oncology. 12(13), 1193-1194. [Abstract]
• Stockler, M., Harvey, V., Francis, P., Byrne, M., Ackland, S., Fitzharris, B., Van Hazel, G., Wilcken, N., Grimison, P., Nowak, A., Gainford, M., Fong, A., Paksec, L., Sourjina, T., Zannino, D., Gebski, V., Simes, R., Forbes, J., Coates, A. (2011), Capecitabine Versus Classical Cyclophosphamide, Methotrexate, and Fluorouracil As First-Line Chemotherapy for Advanced Breast Cancer. Journal of Clinical Oncology. 29(34), 4498-4504. [Abstract]
• Gennari, A., Stockler, M., Puntoni, M., Sormani, M., Nanni, O., Amadori, D., Wilcken, N., D'Amico, M., Decensi, A., Bruzzi, P. (2011), Duration of Chemotherapy for Metastatic Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 29(16), 2144-9. [Abstract]
• Leighl, N., Shepherd, H., Butow, P., Clarke, S., McJannett, M., Beale, P., Wilcken, N., Moore, M., Chen, E., Goldstein, D., Horvath, L., Knox, J., Krzyzanowska, M., Oza, A., Feld, R., Hedley, D., Xu, W., Tattersall, M. (2011), Supporting Treatment Decision Making in Advanced Cancer: A Randomized Trial of a Decision Aid for Patients With Advanced Colorectal Cancer Considering Chemotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 29(15), 2077-84. [Abstract]
• Kiely, B., Wilcken, N., Stockler, M. (2011), Life after adjuvant chemotherapy for breast cancer: the news is mostly good. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 29, 1092-1093. [Abstract]
• de Boer, R., Chan, A., Tran, B., Wilcken, N. (2011), Use of non-anthracycline regimens in early stage breast cancer in Australia. Asia-Pacific Journal of Clinical Oncology. 7(1), 4-10. [Abstract]

2010

• Dickersin, K., Tovey, D., Wilcken, N., Ghersi, D. (2010), The background review for the USPSTF recommendation on screening for breast cancer. Annals of Internal Medicine. , 537; author reply 538-9. [Abstract]
• Dear, R., Tattersall, M., McGeechan, K., Barratt, A., Wilcken, N. (2010), Combination versus sequential single agent chemotherapy for metastatic breast cancer (Protocol). Cochrane Database of Systematic Reviews. 0(10), CD008792.
• Butters, D., Ghersi, D., Wilcken, N., Kirk, S., Mallon, P. (2010), Addition of drug/s to a chemotherapy regimen for metastatic breast cancer. Cochrane Database of Systematic Reviews. 11(1), CD003368. [Abstract]

2009

• Beslija, S., Bonneterre, J., Burstein, H., Cocquyt, V., Gnant, M., Heinemann, V., Jassem, J., Köstler, W., Krainer, M., Menard, S., Petit, T., Petruzelka, L., Possinger, K., Schmid, P., Stadtmauer, E., Stockler, M., Van Belle, S., Vogel, C., Wilcken, N., Wiltschke, C., Zielinski, C., Zwierzina, H. (2009), Third consensus on medical treatment of metastatic breast cancer. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 20(11), 1771-85. [Abstract]
• Goodwin, A., Parker, S., Ghersi, D., Wilcken, N. (2009), Post-operative radiotherapy for ductal carcinoma in situ of the breast--a systematic review of the randomised trials. Breast. 18(3), 143-149. [Abstract]
• Carrick, S., Parker, S., Thornton, C., Ghersi, D., Simes, J., Wilcken, N. (2009), Single agent versus combination chemotherapy for metastatic breast cancer. Cochrane database of systematic reviews. 0(2), CD003372. [Abstract]
• Snyder, R., Boyle, F., Chan, A., Craft, P., De Boer, R., Mainwaring, P., McCarthy, N., Wilcken, N. (2009), Clinical recommendations for the use of lapatinib ditosylate plus capecitabine for patients with advanced or metastatic HER2-positive breast cancer. Asia-Pacific Journal of Clinical Oncology. 5(1), 4-16. [Abstract]
• Goodwin, A., Parker, S., Ghersi, D., Wilcken, N. (2009), Post-operative radiotherapy for ductal carcinoma in situ of the breast. Cochrane database of systematic reviews (Online). 0(4), CD000563. [Abstract]

2008

• Wilcken, N., Dear, R. (2008), Chemotherapy in metastatic breast cancer: A summary of all randomised trials reported 2000-2007. European Journal of Cancer. 44(15), 2218-2225. [Abstract]
• Duric, V., Butow, P., Sharpe, L., Heritier, S., Boyle, F., Beith, J., Wilcken, N., Coates, A., Simes, R., Stockler, M. (2008), Comparing patients' and their partners' preferences for adjuvant chemotherapy in early breast cancer. Patient Education and Counseling. 72(2), 239-245. [Abstract]
• Dear, R., Wilcken, N., Shannon, J. (2008), Beyond chemotherapy--demystifying the new 'targeted' cancer treatments. Australian Family Physician. 37(1-2), 45-49. [Abstract]

2007

• Ahern, V., Boyages, J., Gebski, V., Moon, D., Wilcken, N. (2007), Selective Mastectomy in the Management of Locally Advanced Breast Cancer. International journal of radiation oncology, biology, physics. 68(4), 1010-7. [Abstract]
• Stockler, M., O'connell, R., Nowak, A., Goldstein, D., Turner, J., Wilcken, N., Wyld, D., Abdi, E., Glasgow, A., Beale, P., Jefford, M., Dhillon, H., Heritier, S., Carter, C., Hickie, I., Simes, R. (2007), Effect of sertraline on symptoms and survival in patients with advanced cancer, but without major depression: a placebo-controlled double-blind randomised trial. The lancet oncology. 8(7), 603-612. [Abstract]
• Gurney, H., Wong, M., Balleine, R., Rivory, L., McLachlan, A., Hoskins, J., Wilcken, N., Clarke, C., Mann, G., Collins, M., Delforce, S., Lynch, K., Schran, H. (2007), Imatinib Disposition and ABCB1 (MDR1, P-Glycoprotein) Genotype. Clinical Pharmacology and Therapeutics. 82(1), 33-40. [Abstract]
• Wilcken, N., Stockler, M. (2007), Ovarian suppression for early breast cancer. Lancet. 369(9574), 1668-1670. [Abstract]
• Wilcken, N., Gebski, V., Pike, R., Keech, A. (2007), Putting results of a clinical trial into perspective. The Medical journal of Australia. 186(7), 368-370. [Abstract]
• Beslija, S., Bonneterre, J., Burstein, H., Cocquyt, V., Gnant, M., Goodwin, P., Heinemann, V., Jassem, J., Köstler, W., Krainer, M., Menard, S., Petit, T., Petruzelka, L., Possinger, K., Schmid, P., Stadtmauer, E., Stockler, M., Van Belle, S., Vogel, C., Wilcken, N., Wiltschke, C., Zielinski, C., Zwierzina, H. (2007), Second consensus on medical treatment of metastatic breast cancer. Annals of oncology. 18(2), 215-225. [Abstract]
• Smith, I., Procter, M., Gelber, R., Guillaume, S., Feyereislova, A., Dowsett, M., Goldhirsch, A., Untch, M., Mariani, G., Baselga, J., Kaufmann, M., Cameron, D., Bell, R., Bergh, J., Coleman, R., Wardley, A., Harbeck, N., Lopez, R., Mallmann, P., Gelmon, K., Wilcken, N., Wist, E., Sánchez Rovira, P., Piccart-Gebhart, M. (2007), 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet. 369(9555), 29-36. [Abstract]
• Wilcken, N., Gebski, V., Pike, R., Keech, A. (2007), Putting results of a clinical trial into perspective. In: Interpreting and reporting clinical trials: A guide to the CONSORT statement and the principles of randomised controlled trials. (pp.154-161).Australia: Australasian Medical Publishing Company Ltd..
• Duric, V., Butow, P., Sharpe, L., Boyle, F., Beith, J., Wilcken, N., Heritier, S., Coates, A., John Simes, R., Stockler, M. (2007), Psychosocial factors and patients' preferences for adjuvant chemotherapy in early breast cancer. Psycho-oncology. 16, 48-59. [Abstract]
• Ferguson, T., Wilcken, N., Vagg, R., Ghersi, D., Nowak, A. (2007), Taxanes for adjuvant treatment of early breast cancer. Cochrane database of systematic reviews (Online). CD004421(4), 1-50. [Abstract]
• Keech, A., Pike, R., Wilcken, N., Gebski, V. (2007), Words, words, words - Reply. Medical Journal Of Australia. 187(4), 256-256. [Abstract]